Table 4.
Biomarkers that have not been predictive of the benefit provided by antiangiogenic therapy
| Type of cancer |
Treatment | Study phase |
Study size and time points |
Biomarker findings | |
|---|---|---|---|---|---|
| Antiangiogenic agent |
Cytotoxic agent |
||||
| rGBM | Cediranib | No | II |
n = 31 Pre and post treatment (days 1, 2, 9, 28, 56, 84 and 112) |
No statistically significant relationship between baseline interleukin 8, Ang1, CPC or their changes after treatment and outcome37 |
| Advanced HCC | Sunitinib | No | II |
n = 34 Pre and post treatment (days 14, 28, 56, 84 and 112) |
No statistically significant relationship between baseline PIGF, bFGF and VEGF-C or their changes after treatment and outcome23 |
| Advanced RC | Bevacizumab | 5-FU EBRT |
II |
n = 32 Pre and post treatment (days 3, 12 after blood volume alone, 33, and 96) |
No statistically significant relationship between baseline interleukin 8, bFGF, CPC or their changes after treatment and outcome22 |
| mCRC | Bevacizumab | IFL | III |
n = 312 Baseline |
No statistically significant relationship between VEGF, thrombospondin-2 or microvessel density and the increase in median overall survival40 |
| mCRC | Bevacizumab | IFL | II–III |
n = 295 Baseline |
No statistically significant relationship between mutations of KRAS, BRAF, or P53 and the increase in median overall survival59 |
| mNSCLC | Bevacizumab | Carboplatin and paclitaxel |
III |
n = 56–166 Pre and post treatment (week 7) |
No statistically significant relationship between baseline VEGF and bFGF or their changes at week 7 and outcome41 |
Abbreviations: bFGF, basic fibroblast growth factor; CPC, circulating progenitor cell; EBRT, external beam radiation therapy; 5-FU, five fluorouracil; HCC hepatocellular carcinoma; IFL, irinotecan, 5-FU and leucovorin; mCRC, metastatic colorectal cancer; mNSCLC, metastatic non-small-cell lung cancer; PIGF, placental growth factor; RC, rectal cancer; RCC, renal cell carcinoma; rGBM, recurrent glioblastoma.